AU2003301439A1 - Pre-organized tricyclic integrase inhibitor compounds - Google Patents

Pre-organized tricyclic integrase inhibitor compounds

Info

Publication number
AU2003301439A1
AU2003301439A1 AU2003301439A AU2003301439A AU2003301439A1 AU 2003301439 A1 AU2003301439 A1 AU 2003301439A1 AU 2003301439 A AU2003301439 A AU 2003301439A AU 2003301439 A AU2003301439 A AU 2003301439A AU 2003301439 A1 AU2003301439 A1 AU 2003301439A1
Authority
AU
Australia
Prior art keywords
inhibitor compounds
integrase inhibitor
organized
tricyclic integrase
organized tricyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003301439A
Other languages
English (en)
Other versions
AU2003301439A8 (en
Inventor
James M. Chen
Xiaowu Chen
Maria Fardis
Haolun Jin
Choung U. Kim
Laura N. Schacherer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AU2003301439A8 publication Critical patent/AU2003301439A8/xx
Publication of AU2003301439A1 publication Critical patent/AU2003301439A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2003301439A 2002-10-16 2003-10-15 Pre-organized tricyclic integrase inhibitor compounds Abandoned AU2003301439A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41896302P 2002-10-16 2002-10-16
US60/418,963 2002-10-16
US47878303P 2003-06-16 2003-06-16
US60/478,783 2003-06-16
PCT/US2003/032866 WO2004035577A2 (en) 2002-10-16 2003-10-15 Pre-organized tricyclic integrase inhibitor compounds

Publications (2)

Publication Number Publication Date
AU2003301439A8 AU2003301439A8 (en) 2004-05-04
AU2003301439A1 true AU2003301439A1 (en) 2004-05-04

Family

ID=32110203

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003301439A Abandoned AU2003301439A1 (en) 2002-10-16 2003-10-15 Pre-organized tricyclic integrase inhibitor compounds
AU2003301306A Abandoned AU2003301306A1 (en) 2002-10-16 2003-10-16 Pre-organized tricyclic integrase inhibitor compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2003301306A Abandoned AU2003301306A1 (en) 2002-10-16 2003-10-16 Pre-organized tricyclic integrase inhibitor compounds

Country Status (19)

Country Link
US (3) US20040157804A1 (enExample)
EP (1) EP1558613A2 (enExample)
JP (1) JP2006514099A (enExample)
KR (1) KR20050087787A (enExample)
CN (1) CN100374438C (enExample)
AP (1) AP1858A (enExample)
AU (2) AU2003301439A1 (enExample)
BR (1) BR0315405A (enExample)
CA (1) CA2501881A1 (enExample)
EA (1) EA011399B1 (enExample)
HR (1) HRP20050431A2 (enExample)
IS (1) IS7845A (enExample)
MX (1) MXPA05003950A (enExample)
NO (1) NO20052378L (enExample)
NZ (1) NZ539264A (enExample)
OA (1) OA13079A (enExample)
PL (1) PL377966A1 (enExample)
UA (1) UA79830C2 (enExample)
WO (2) WO2004035577A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071102A2 (en) * 1999-05-19 2000-11-30 Neurosearch A/S Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
CN1812992A (zh) * 2003-04-28 2006-08-02 泰博特克药品有限公司 Hiv整合酶抑制剂
ATE433974T1 (de) 2003-09-19 2009-07-15 Gilead Sciences Inc Azachinolinolphosphonatverbindungen als integraseinhibitoren
CA2547418A1 (en) * 2003-12-08 2005-06-23 The Research Foundation Of State University Of New York Site selectively tagged and templated molecularly imprinted polymers for sensor applications
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7598087B2 (en) * 2004-01-07 2009-10-06 The Research Foundation Of State University Of New York Protein imprinted polymers with integrated emission sites
SI1742642T1 (sl) * 2004-04-14 2009-04-30 Gilead Sciences Inc Fosfonatni analogi inhibitorskih spojin HIV integraze
ES2529038T3 (es) * 2004-05-07 2015-02-16 Merck Sharp & Dohme Corp. Inhibidores de la integrasa de VIH
US7476666B2 (en) 2004-06-09 2009-01-13 Merck & Co., Inc. HIV integrase inhibitors
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
US7745459B2 (en) 2004-09-21 2010-06-29 Japan Tobacco Inc. Quinolizinone compound and use thereof as HIV integrase inhibitor
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20070072831A1 (en) * 2005-05-16 2007-03-29 Gilead Sciences, Inc. Integrase inhibitor compounds
ATE533766T1 (de) 2005-05-19 2011-12-15 Merck Canada Inc Chinolinderivate als ep4-antagonisten
AU2006272521A1 (en) * 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of HIV
WO2007019130A2 (en) * 2005-08-04 2007-02-15 Smithkline Beecham Corporation Hiv integrase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1973908A2 (en) * 2005-12-21 2008-10-01 Gilead Sciences, Inc. Processes and intermediates useful for preparing integrase inhibitor compounds
US20070219243A1 (en) 2005-12-30 2007-09-20 Kearney Brian P Method for improving the pharmacokinetics of HIV integrase inhibitors
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
WO2007136714A2 (en) * 2006-05-16 2007-11-29 Gilead Sciences, Inc. Integrase inhibitors
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
US20090291921A1 (en) * 2007-11-20 2009-11-26 Gilead Sciences, Inc. Integrase inhibitors
CN105055432A (zh) 2008-01-25 2015-11-18 奇默里克斯公司 治疗病毒感染的方法
EP2660239B1 (en) 2008-07-25 2016-11-23 VIIV Healthcare Company Chemical compounds as synthetic intermediates
AU2009276744A1 (en) * 2008-07-28 2010-02-04 Polymedix, Inc. Anti-malarial compounds
SG171308A1 (en) 2008-12-11 2011-07-28 Shionogi & Co Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
EP3617194B1 (en) 2008-12-11 2023-11-08 VIIV Healthcare Company Processes and intermediates for carbamoylpyridone hiv integrase inhibitors
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
EP2270021A1 (en) * 2009-06-18 2011-01-05 Centre National de la Recherche Scientifique Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability
WO2011011483A1 (en) * 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
WO2011045330A1 (en) 2009-10-13 2011-04-21 Tibotec Pharmaceuticals Macrocyclic integrase inhibitors
JP5745869B2 (ja) * 2010-01-22 2015-07-08 富山化学工業株式会社 アルアルキル基を有する複素環化合物
US8283366B2 (en) 2010-01-22 2012-10-09 Ambrilia Biopharma, Inc. Derivatives of pyridoxine for inhibiting HIV integrase
CA2789443C (en) 2010-02-12 2016-09-13 Chimerix, Inc. Nucleoside phosphonate salts
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
TWI503323B (zh) 2010-03-29 2015-10-11 Oncotherapy Science Inc 三環化合物以及含此化合物之ｐｂｋ抑制劑
WO2011121105A1 (en) 2010-04-02 2011-10-06 Tibotec Pharmaceuticals Macrocyclic integrase inhibitors
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
KR101365849B1 (ko) * 2012-03-28 2014-02-24 경동제약 주식회사 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
KR102000382B1 (ko) 2015-02-03 2019-07-15 화이자 인코포레이티드 신규 시클로프로파벤조푸라닐 피리도피라진디온
CN104803905B (zh) * 2015-04-17 2017-10-10 复旦大学 一种合成异吲哚啉‑1‑酮衍生物的方法
WO2017133517A1 (zh) * 2016-02-03 2017-08-10 四川海思科制药有限公司 一种磷酰胺衍生物及制备方法和用途
CN109305989B (zh) * 2017-07-28 2021-02-26 四川海思科制药有限公司 一种磷酰胺衍生物及制备方法和用途
CN109305990B (zh) * 2017-07-28 2021-02-26 四川海思科制药有限公司 一种磷酸衍生物及制备方法和用途
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH385846A (de) 1960-03-31 1964-12-31 Geigy Ag J R Verfahren zur Herstellung von neuen 7-Acyl-8-hydroxy-chinolinen und ihre Verwendung als Fungizide und Bakterizide im Pflanzen- und Materialschutz
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
ES2083580T3 (es) 1990-06-13 1996-04-16 Arnold Glazier Profarmacos de fosforo.
DK0481214T3 (da) 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prolægemidler af phosphonater
ATE156120T1 (de) 1991-02-07 1997-08-15 Roussel Uclaf Bizyklische stickstoffverbindungen, ihre herstellung, erhaltene zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen
EP0520573A1 (en) 1991-06-27 1992-12-30 Glaxo Inc. Cyclic imide derivatives
US5639881A (en) * 1991-11-08 1997-06-17 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis and elucidation of pyrimido (4,5-Q) quinazoline derivatives
TW304945B (enExample) 1992-06-27 1997-05-11 Hoechst Ag
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US5538988A (en) 1994-04-26 1996-07-23 Martinez; Gregory R. Benzocycloalkylazolethione derivatives
US5854275A (en) 1996-05-16 1998-12-29 Pfizer Inc. Cyclic imide derivatives
AU4172197A (en) 1996-09-10 1998-04-02 Pharmacia & Upjohn Company 8-hydroxy-7-substituted quinolines as anti-viral agents
WO1999007701A1 (en) * 1997-08-05 1999-02-18 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
AU4225499A (en) 1998-06-03 1999-12-20 Merck & Co., Inc. Hiv integrase inhibitors
WO1999062513A1 (en) 1998-06-03 1999-12-09 Merck & Co., Inc. Hiv integrase inhibitors
US6218402B1 (en) * 1998-06-10 2001-04-17 Arena Pharmaceuticals, Inc. Acetylcholine enhancers
US6187907B1 (en) 1998-08-31 2001-02-13 James Chen Triple helix coil template having a biologically active ligand
WO2000036132A1 (en) 1998-12-14 2000-06-22 Merck & Co., Inc. Hiv integrase inhibitors
BR9916583A (pt) 1998-12-25 2001-09-25 Shionogi & Co Derivados heteroaromáticos tendo uma atividade inibitória contra integrase de hiv
EP1186599A4 (en) 1999-06-02 2003-02-26 Shionogi & Co NOVEL PROCESS FOR THE PREPARATION OF SUBSTITUTED PROPENONE DERIVATIVES
WO2001000578A1 (en) 1999-06-25 2001-01-04 Merck & Co., Inc. 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof
US6245806B1 (en) 1999-08-03 2001-06-12 Merck & Co., Inc. HIV integrase inhibitors
AU8009900A (en) 1999-10-13 2001-04-23 Merck & Co., Inc. Hiv integrase inhibitors
JP2004517860A (ja) 2000-10-12 2004-06-17 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類
EP1326865B1 (en) * 2000-10-12 2009-05-06 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
AU1532802A (en) * 2000-10-12 2002-04-22 Merck & Co Inc Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
AU2002230392A1 (en) 2000-10-12 2002-05-15 Merck & Co., Inc. AZA-and polyaza-naphthalenyl ketones useful as HIV integrase inhibitors
AU2002215018A1 (en) * 2000-10-13 2002-04-22 Bayer Aktiengesellschaft Human histone deacetylase gene
US6518767B1 (en) * 2000-10-19 2003-02-11 Schweitzer Engineering Laboratories, Inc. Line differential protection system for a power transmission line
SI1742642T1 (sl) * 2004-04-14 2009-04-30 Gilead Sciences Inc Fosfonatni analogi inhibitorskih spojin HIV integraze

Also Published As

Publication number Publication date
US20090029939A1 (en) 2009-01-29
EP1558613A2 (en) 2005-08-03
BR0315405A (pt) 2005-08-09
US20040167124A1 (en) 2004-08-26
WO2004035577A3 (en) 2004-07-29
PL377966A1 (pl) 2006-02-20
AP1858A (en) 2008-06-30
AU2003301439A8 (en) 2004-05-04
EA200500660A1 (ru) 2005-10-27
CA2501881A1 (en) 2004-04-29
AU2003301306A1 (en) 2004-05-04
OA13079A (en) 2006-11-10
WO2004035576A3 (en) 2004-06-24
WO2004035577A2 (en) 2004-04-29
KR20050087787A (ko) 2005-08-31
NZ539264A (en) 2007-08-31
WO2004035576A2 (en) 2004-04-29
EA011399B1 (ru) 2009-02-27
MXPA05003950A (es) 2005-06-17
AP2005003279A0 (en) 2005-06-30
UA79830C2 (en) 2007-07-25
NO20052378D0 (no) 2005-05-13
US20040157804A1 (en) 2004-08-12
IS7845A (is) 2005-05-13
JP2006514099A (ja) 2006-04-27
US7253180B2 (en) 2007-08-07
NO20052378L (no) 2005-07-18
HRP20050431A2 (en) 2005-10-31
CN1726212A (zh) 2006-01-25
CN100374438C (zh) 2008-03-12

Similar Documents

Publication Publication Date Title
AP2005003279A0 (en) Pre-organized tricyclic integrase inhibitor compounds
AUPS137402A0 (en) Novel tricyclic compounds
AU2003266949A1 (en) Compounds
AU2003301302A1 (en) Pyradazine compounds as gsk-3 inhibitors
AU2003248872A1 (en) Hiv integrase inhibitors
AU2003221098A1 (en) Oligofluorenylene compounds
AU2003290734A1 (en) Novel compounds as pharmaceutical agents
AU2003279366A1 (en) Novel compounds
AU2003273064A1 (en) Quinoline-3-carboxamide compound
AU2003277674A1 (en) Novel parp inhibitors
AU2003215635A1 (en) Thiazol-2-yl-imine compounds as pde-7 inhibitors
AU2003216859A1 (en) Amidoacetonitrile compounds
AU2003236093A1 (en) Composition for preventing arteriosclerosis
HK1077304A (en) Pre-organized tricyclic integrase inhibitor compounds
AU2003251259A1 (en) Novel compounds
AU2003255834A1 (en) Luminescent compounds
AU2003248246A1 (en) Hetero-bicyclic compounds
AU2003291021A1 (en) Arylpyridine compounds
AU2003292667A1 (en) Benzocycloheptapyridine compounds
AU2003255322A1 (en) Compounds
AU2003275480A1 (en) Compounds
HK1091836A (en) Aza-quinolinol phosphonate integrase inhibitor compounds
AU2003226541A1 (en) Novel compounds
HK1071135A (en) Tricyclic n-acyl compounds
HK1082763A (en) Novel compounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase